Catalent (CTLT) Misses Q4 EPS by 1c, FY17 Revenue Guidance Tops Views at Mid-Point
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Catalent, Inc. Reports Fourth Quarter and Fiscal Year 2016 Results
August 29, 2016 4:15 PM EDTQ4'16 revenue $532.2 million increased 6% in constant currency from the prior year period FY'16 revenue of $1.85 billion increased 6% in constant currency from the prior year period Catalent's proprietary OptiShell softgel technology has been selected for use in OPKO Health's NDA for RAYALDEE® and has been approved by the U.S. FDA Announced the launch of our FastChain service, for greater speed, flexibility and efficiency in the management and distribution of global clinical trial supplies... More
